Floatz logo

cd70-targeting car-t cells

Gynecologic Cancer

Chongqing Precision Biotech Co., LtdCell therapyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

51 Active assets in the Gynecologic Cancer cohort.

Asset / SponsorPhaseRating
Inno-206
AstraZeneca
Phase 2BB
Carboplatin
AbbVie
Phase 2/3BB
Indocyanine Green
Istanbul University
Phase 4BB
Ringer's acetate
Joachim Zdolsek
Phase 4B
Nivolumab
Clovis Oncology, Inc.
Phase 2B

View all 50 →

Same molecule, other indications

cd70-targeting car-t cells is also rated in:

lymphomaDormant
CC
Indicative ·
46 / 100
View asset →
metastatic neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
cervical cancerDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →